research Current and Potential Agents for the Treatment of Alopecia Areata>
Current and future treatments for alopecia areata focus on immunosuppression, immunomodulation, and protecting hair follicles.
Search
for
Sort by
Research
960-990 / 1000+ results 
research Therapeutic synergy between contact dermatitis from a wig‐fixing device and tofacitinib on alopecia areata
A man's hair regrew from alopecia areata after using tofacitinib and experiencing contact dermatitis from a wig device.
research Targeting the Wnt pathways for therapies
Blocking the Wnt pathway could lead to new treatments for cancer and tissue repair but requires careful development to avoid side effects.
research 128 Bimekizumab led to rapid & deep normalisation of molecular signatures associated with PASI sub-components, preceding clinical skin clearance
Bimekizumab quickly improves psoriasis symptoms and skin at the molecular level.
research A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes
Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
research Dermpath & Clinic: Telangiectasia macularis eruptiva perstans
Brodalumab is more effective than ustekinumab in treating psoriasis.
research Hydroxysteroid Dehydrogenase (17β -HSD3, 17β-HSD5, and 3α-HSD3) Inhibitors:Extragonadal Regulation of Intracellular Sex Steroid Hormone Levels
Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.
research Therapeutic Burden as Predictor of Response to Baricitinib for Alopecia Areata in Real Life: Prospective Study
Patients with fewer past treatments for alopecia areata respond better to baricitinib.
research ROCK inhibitor Y-27632 maintains the propagation and characteristics of hair follicle stem cells.
Y-27632 helps hair follicle stem cells grow and keep their abilities.
research Oral abrocitinib for treatment of refractory alopecia areata: A retrospective study
Abrocitinib may help treat alopecia areata effectively with mild side effects.
research Investigation on antimicrobial, antioxidant, and anti-cancerous activity of Agaricus bisporus derived β-Glucan against cervical cancer cell line
Agaricus bisporus derived β-Glucan could be an effective cervical cancer treatment with antimicrobial and antioxidant properties.
research Circumscribed Alopecia Areata Incognita and Response to Tofacitinib
Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.
research Effect of tofacitinib on the expression of noggin/BMP-4 and hair growth stimulation in mice
Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.
research Alex de la Iglesia: "Todos somos perversos"
Bcl-2 affects hair growth and pigmentation by controlling cell death.
research Beyond DNA-targeting in Cancer Chemotherapy. Emerging Frontiers - A Review
New cancer treatments aim to reduce side effects and improve effectiveness.
research Inhibidor janus kinasa como opción terapéutica en alopecia areata. Reporte de caso
Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.
research COVID-19: The question of genetic diversity and therapeutic intervention approaches
COVID-19 treatments and vaccines face challenges due to genetic differences in people and the virus.
research Cepharanthine Inhibits Doxorubicin-Induced Cellular Senescence by Activating Autophagy via the mTOR Signaling Pathway
Cepharanthine helps reduce cell aging caused by the cancer drug Doxorubicin by boosting cell cleanup processes.
research Circulating monocytes as a marker of response to adalimumab in patients with hidradenitis suppurativa
This retrospective study of 143 patients with hidradenitis suppurativa (HS) treated with adalimumab found that baseline monocyte counts can predict treatment effectiveness. Patients with monocyte counts \(\geq\) 925/\(\mu\)l had a significantly higher risk of adalimumab ineffectiveness, with a hazard ratio of 5.87. Drug survival rates at 12 and 24 months were significantly higher in patients with lower monocyte counts, at 95.7% and 90.6%, compared to 61.5% and 52.7% in those with higher counts. The optimal monocyte count cut-off for predicting response was \(\geq\) 925/\(\mu\)l, with a specificity of 90.5% and sensitivity of 46.2%. Other factors like age, BMI, and HS severity did not significantly affect treatment outcomes.
research Therapy for Alopecia Areata in Mice by Stimulating the Hair Cycle with Parathyroid Hormone Agonists Linked to a Collagen-Binding Domain
PTH-CBD helps reduce hair loss in mice by stimulating hair growth directly.
research 413 DC-HIL+ myeloid-derived suppressor cells are elevated in the peripheral blood and lesional skin of cutaneous lupus patients
Cutaneous lupus patients have higher levels of certain immune cells in their blood and skin.
research Long‐Term Real‐World Outcomes of Baricitinib in Severe Alopecia Areata: A 104‐Week Retrospective Analysis From a Single Institute
Baricitinib is effective and safe for long-term treatment of severe alopecia areata.
research Case Report: Baricitinib improved alopecia areata in a pediatric patient with atopic dermatitis
Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.
research Design, synthesis and anti-tumor evaluation of novel thiohydantoin congeners as androgen receptor antagonists with in vivo study.
A new compound, 3a, effectively fights prostate cancer better than finasteride.
research CD34 Expression by Hair Follicle Stem Cells Is Required for Skin Tumor Development in Mice
CD34 is crucial for skin tumor development in mice.
research Cyclosporine Therapy for Bullous Erythema Multiforme
Cyclosporine cleared a woman's resistant skin condition quickly and kept it away for over a year.
research Successful treatment of palmoplantar pustular psoriasis with brodalumab
Brodalumab effectively treated a man's severe hand and foot psoriasis.
research EX VIVO DRUG SENSITIVITY EVALUATION OF A RARE ZMYM2::FGFR1+ LEUKEMIA PATIENT
Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.
research A Real-World Study of Steroid-Free Monotherapy with Tofacitinib in Severe and Therapy-Recalcitrant Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Cases: A Retrospective Analysis
Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
research miR-29a-5p Inhibits Prenatal Hair Placode Formation Through Targeting EDAR by ceRNA Regulatory Network
miR-29a-5p prevents the formation of early hair structures by targeting a gene important for hair growth and is regulated by a complex network involving lncRNA627.1.